Chronic exposure to arsenic and markers of cardiometabolic risk: A cross-sectional study in Chihuahua, Mexico

Environmental Health Perspectives

Volumn 124, Issue 1, 2016, Pages 104-111

  Mendez, Michelle A ^a,b,c   González Horta, Carmen ^d   Sánchez Ramírez, Blanca ^d   Ballinas Casarrubias, Lourdes ^d   Cerón, Roberto Hernández ^e   Morales, Damián Viniegra ^e   Baeza Terrazas, Francisco A ^e   Ishida, María C ^c   Gutiérrez Torres, Daniela S ^c   Saunders, R Jesse ^a   Drobná, Zuzana ^a   Fry, Rebecca C ^a,c   Buse, John B ^f   Loomis, Dana ^g   García Vargas, Gonzalo G ^h   Del Razo, Luz M ⁱ   Stýblo, Miroslav ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA   (Mexico)

^e Monographs Section ^*  (Mexico)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

ⁱ DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CACODYLIC ACID; CREATININE; DRINKING WATER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLARSENIC; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WATER POLLUTANT;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD PRESSURE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSGLYCEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIMIT OF DETECTION; LONG TERM EXPOSURE; MALE; MEXICO; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; QUESTIONNAIRE; URINALYSIS; WATER POLLUTION; BLOOD; CARDIOVASCULAR DISEASE; STATISTICAL MODEL; TOXICITY; WATER POLLUTANT;

ADULT; ARSENIC; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; LINEAR MODELS; MALE; MEXICO; MIDDLE AGED; WATER POLLUTANTS, CHEMICAL;

EID: 84952657249     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1408742     Document Type: Article

References (68)

1. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. 2012. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 120:494–500; doi:10.1289/ehp.1103988.
2. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. 2001. High preva-lence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 42:1298–1307.
3. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, et al. 2007. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 16:1270–1278.
4. Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo-Arvizu R, Kanter R, et al. 2009. Obesity and central adiposity in Mexican adults: results from the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex 51(suppl 4):S595–S603.
5. Calatayud M, Gimeno-Alcañiz JV, Vélez D, Devesa V. 2014. Trivalent arsenic species induce changes in expression and levels of proinflammatory cytokines in intestinal epithelial cells. Toxicol Lett 224:40–46.
6. Chen JW, Wang SL, Wang YH, Sun CW, Huang YL, Chen CJ, et al. 2012. Arsenic methylation, GSTO1 polymorphisms, and metabolic syndrome in an arseniasis endemic area of southwestern Taiwan. Chemosphere 88:432–438.
7. Chen Y, Factor-Litvak P, Howe GR, Graziano JH, Brandt-Rauf P, Parvez F, et al. 2007. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. Am J Epidemiol 165:541–552.
8. Chen Y, Graziano JH, Parvez F, Liu M, Slavkovich V, Kalra T, et al. 2011. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ 342:d2431; doi:10.1136/bmj.d2431.
9. Chen Y, Wu F, Graziano JH, Parvez F, Liu M, Paul RR, et al. 2013a. Arsenic exposure from drinking water, arsenic methylation capacity, and carotid intima- media thickness in Bangladesh. Am J Epidemiol 178:372–381.
10. Chen Y, Wu F, Liu M, Parvez F, Slavkovich V, Eunus M, et al. 2013b. A prospective study of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ Health Perspect 121:832–838; doi:10.1289/ehp.1205797.
11. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, et al. 2003a. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248.
12. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, et al. 2003b. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310.
13. Cheng TJ, Chuu JJ, Chang CY, Tsai WC, Chen KJ, Guo HR. 2011. Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. Toxicol Appl Pharmacol 256:146–153.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252.
15. Currier JM, Ishida MC, González-Horta C, Sánchez- Ramírez B, Ballinas-Casarrubias L, Gutiérrez- Torres DS, et al. 2014. Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. Environ Health Perspect 122:1088–1094; doi:10.1289/ehp.1307756.
16. Del Razo LM, García-Vargas GG, Valenzuela OL, Castellanos EH, Sánchez-Peña LC, Currier JM, et al. 2011. Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapán and Lagunera regions in Mexico. Environ Health 10:73; doi:10.1186/1476-069X-10-73.
17. Del Razo LM, García-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, et al. 1997. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol 71:211–217.
18. Dirección General de Normas (DGN). 1994. NOM-127-SSA. Norma oficial mexicana. Salud ambiental, agua para uso y consumo humano- límites permisibles de calidad y tratamientos a que debe someterse el agua para su potabilización [in Spanish]. Diario oficial de la federación. México.
19. Douillet C, Currier J, Saunders J, Bodnar WM, Matoušek T, Stýblo M. 2013. Methylated trivalent arsenicals are potent inhibitors of glucose stimu-lated insulin secretion by murine pancreatic islets. Toxicol Appl Pharmacol 267:11–15.
20. Druwe IL, Sollome JJ, Sanchez-Soria P, Hardwick RN, Camenisch TD, Vaillancourt RR. 2012. Arsenite activates NFκB through induction of C-reactive protein. Toxicol Appl Pharmacol 261:263–270.
21. Fu J, Woods CG, Yehuda-Shnaidman E, Zhang Q, Wong V, Collins S, et al. 2010. Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect 118:864–870.
22. Genest J. 2008. The Yin and Yang of high-density lipo-protein cholesterol. J Am Coll Cardiol 51:643–644.
23. Gribble MO, Howard BV, Umans JG, Shara NM, Francesconi KA, Goessler W, et al. 2012. Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Am J Epidemiol 176:865–874.
24. Hernández-Zavala A, Matoušek T, Drobná Z, Paul DS, Walton F, Adair BM, et al. 2008. Speciation analysis of arsenic in biological matrices by auto-mated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectrom 23:342–351.
25. Hossain E, Ota A, Karnan S, Damdindorj L, Takahashi M, Konishi Y, et al. 2013. Arsenic augments the uptake of oxidized LDL by upregu-lating the expression of lectin-like oxidized LDL receptor in mouse aortic endothelial cells. Toxicol Appl Pharmacol 273:651–658.
26. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. 2007. Arsenic methylation capa-bility and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol Appl Pharmacol 218:135–142.
27. Islam MR, Khan I, Attia J, Hassan SM, McEvoy M, D’Este C, et al. 2012. Association between hyper-tension and chronic arsenic exposure in drinking water: a cross-sectional study in Bangladesh. Int J Environ Res Public Health 9:4522–4536.
28. James KA, Marshall JA, Hokanson JE, Meliker JR, Zerbe GO, Byers TE. 2013. A case-cohort study examining lifetime exposure to inorganic arsenic in drinking water and diabetes mellitus. Environ Res 123:33–38.
29. Jones MR, Tellez-Plaza M, Sharrett AR, Guallar E, Navas-Acien A. 2011. Urine arsenic and hyperten-sion in US adults: the 2003–2008 National Health and Nutrition Examination Survey. Epidemiology 22:153–161.
30. Karim MR, Rahman M, Islam K, Mamun AA, Hossain S, Hossain E, et al. 2013. Increases in oxidized low- density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol Sci 135:17–25.
31. Kim NH, Mason CC, Nelson RG, Afton SE, Essader AS, Medlin JE, et al. 2013. Arsenic exposure and incidence of type 2 diabetes in Southwestern American Indians. Am J Epidemiol 177:962–969.
32. Kunrath J, Gurzau E, Gurzau A, Goessler W, Gelmann ER, Thach TT, et al. 2013. Blood pressure hyperreac-tivity: an early cardiovascular risk in normotensive men exposed to low-to-moderate inorganic arsenic in drinking water. J Hypertens 31:361–369.
33. Kuo CC, Moon K, Thayer KA, Navas-Acien A. 2013. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep 13:831–849.
34. Lemaire M, Lemarié CA, Molina MF, Schiffrin EL, Lehoux S, Mann KK. 2011. Exposure to moderate arsenic concentrations increases atherosclerosis in ApoE–/–mouse model. Toxicol Sci 122:211–221.
35. Li X, Li B, Xi S, Zheng Q, Lv X, Sun G. 2013a. Prolonged environmental exposure of arsenic through drinking water on the risk of hypertension and type 2 diabetes. Environ Sci Pollut Res Int 20:8151–8161.
36. Li X, Li B, Xi S, Zheng Q, Wang D, Sun G. 2013b. Association of urinary monomethylated arsenic concentration and risk of hypertension: a crosssectional study from arsenic contaminated areas in northwestern China. Environ Health 12:37; doi:10.1186/1476-069X-12-37.
37. Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, Pi J, et al. 2012. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect 120:1658–1670; doi:10.1289/ehp.1104579.
38. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. 2011. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123:2292–2333.
39. Moon K, Guallar E, Navas-Acien A. 2012. Arsenic exposure and cardiovascular disease: an updated systematic review. Curr Atheroscler Rep 14:542–555.
40. Moon KA, Guallar E, Umans JG, Devereux RB, Best LG, Francesconi KA, et al. 2013. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann Intern Med 159:649–659.
41. Morales LS, Flores YN, Leng M, Sportiche N, Gallegos- Carrillo K, Salmerón J. 2014. Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study. Salud Publica Mex 56:197–205.
42. Muthumani M, Prabu SM. 2014. Silibinin potentially attenuates arsenic-induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. Cardiovasc Toxicol 14:83–97.
43. National Institute of Standards and Technology. 2008. Development of SRM 2669 for Accurate Assessment of Arsenic Exposure. Available: http://www.nist.gov/mml/csd/inorganic/arsenicurine.cfm [accessed 1 July 2014].
44. Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, et al. 2005. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 162:1037–1049.
45. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. 2008. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 300:814–822.
46. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. 2009. Rejoinder: arsenic exposure and prevalence of type 2 diabetes: updated findings from the National Health Nutrition and Examination Survey, 2003–2006. Epidemiology 20:816–820.
47. Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E. 2006. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114:641–648; doi:10.1289/ehp.8551.
48. NCEP [National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)]. 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Final Report. Circulation 106:3143–3421.
49. Nizam S, Kato M, Yatsuya H, Khalequzzaman M, Ohnuma S, Naito H, et al. 2013. Differences in urinary arsenic metabolites between diabetic and non-diabetic subjects in Bangladesh. Int J Environ Res Public Health 10:1006–1019.
50. Oliveira MJ, van Deventer HE, Bachmann LM, Warnick GR, Nakajima K, Nakamura M, et al. 2013. Evaluation of four different equations for calculating LDL-C with eight different direct HDL-C assays. Clin Chim Acta 423:135–140.
51. Pan WC, Seow WJ, Kile ML, Hof fman EB, Quamruzzaman Q, Rahman M, et al. 2013. Association of low to moderate levels of arsenic exposure with risk of type 2 diabetes in Bangladesh. Am J Epidemiol 178:1563–1570.
52. Paramsothy P, Knopp RH, Bertoni AG, Blumenthal RS, Wasserman BA, Tsai MY, et al. 2010. Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 56:1034–1041.
53. Paul DS, Hernández-Zavala A, Walton FS, Adair BM, Dedina J, Matousek T, et al. 2007. Examination of the effects of arsenic on glucose homeostasis in cell culture and animal studies: development of a mouse model for arsenic-induced diabetes. Toxicol Appl Pharmacol 222:305–314.
54. Pierce BL, Tong L, Argos M, Gao J, Farzana J, Roy S, et al. 2013. Arsenic metabolism efficiency has a causal role in arsenic toxicity: Mendelian randomization and gene-environment interaction. Int J Epidemiol 42:1862–1871.
55. Salas R, Bibiloni Mdel M, Ramos E, Villarreal JZ, Pons A, Tur JA, et al. 2014. Metabolic syndrome prevalence among Northern Mexican adult population. PloS One 9:e105581; doi:10.1371/journal.pone.0105581.
56. Sanchez-Soria P, Broka D, Monks SL, Camenisch TD. 2012. Chronic low-level arsenite exposure through drinking water increases blood pressure and promotes concentric left ventricular hypertrophy in female mice. Toxicol Pathol 40:504–512.
57. Stýblo M, Drobná Z, Jaspers I, Lin S, Thomas DJ. 2002. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect 110(suppl 5):767–771.
58. Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, et al. 2007. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood) 232:3–13.
59. Tseng CH. 2007. Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:1–22.
60. U.S. EPA (U.S. Environmental Protection Agency). 2014. Arsenic in Drinking Water. Available: http://water.epa.gov/lawsregs/rulesregs/sdwa/arsenic/index.cfm [accessed 2 June 2015].
61. Vanderweele TJ, Knol MJ. 2014. A tutorial on inter-action. Epidemiol Method 3:79–81.
62. Vickers KC, Remaley AT. 2014. HDL and cholesterol: life after the divorce? J Lipid Res 55:4–12.
63. Villalpando S, Shamah-Levy T, Rojas R, Aguilar- Salinas CA. 2010. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993–2006. Salud Publica Mex 52(suppl 1):S72–S79.
64. Wang SL, Chang FH, Liou SH, Wang HJ, Li WF, Hsieh DP. 2007. Inorganic arsenic exposure and its relation to metabolic syndrome in an industrial area of Taiwan. Environ Int 33:805–811.
65. WHO (World Health Organization) Expert Committee on Physical Status. 1995. Physical Status: The Use and Interpretation of Anthropometry: Report of a WHO Expert Committee. Technical report series No. 854 Geneva:World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/37003/1/WHO_TRS_854.pdf [accessed 1 October 2014].
66. WHO/International Diabetes Federation. 2006. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva: World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/43588/1/9241594934_eng.pdf [accessed 1 October 2014].
67. Wu F, Jasmine F, Kibriya MG, Liu M, Wójcik O, Parvez F, et al. 2012. Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol 175:1252–1261.
68. Yu RC, Hsu KH, Chen CJ, Froines JR. 2000. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262.